Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MKTW$19.58+0.75(+3.98%)MarketWise, Inc. Declares Quarterly Dividend on Class A Common Stock of $0.45 Per Share[9:00:14 AM ET]UFPI$80.93-0.30(-0.37%)UFP Packaging Expands Gulf Coast Pallet Network with Acquisition of Apache Products UFP Packaging, a division of UFP Industries (Nasdaq: UFPI), announced this week the acquisition of Apache Products, Inc., a pallet producer based in...[9:00:00 AM ET]THFF$77.70+1.24(+1.62%)First Financial Corporation Reports Third Quarter Results[9:00:00 AM ET]FTNT$181.84-1.49(-0.81%)Fortinet Expands Unified SASE to Simplify Microbranch Security[9:00:00 AM ET]VELO$6.61+0.12(+1.85%)Velo3D to Announce Third Quarter 2026 Results on November 10, 2026 Velo3D, Inc. (Nasdaq: VELO), a leading metal additive manufacturing technology company, today announced that it will release its third quarter 2026...[9:00:00 AM ET]CPB$20.64+0.01(+0.05%)Campbell's® Marks Five Years of Sides Season™ with Its Annual State of the Sides Report Campbell's officially kicked off Sides Season™ with the release of its 2026 State of the Sides Report. Now in its fifth year, the report offers a...[9:00:00 AM ET]TENB$47.55-0.66(-1.37%)Tenable Selected by Atos to Power Continuous Threat Exposure Management Program[9:00:00 AM ET]PLUR$1.23+0.11(+9.82%)Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments[9:00:00 AM ET]ATYR$0.12-0.04(-24.45%)aTyr Pharma Announces One-for-40 Reverse Stock Split[9:00:00 AM ET]KD$14.70+0.02(+0.14%)Kyndryl Opens New Cyber Defense Operations Center in Paris Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today unveiled a new Cyber Defense Operations Center in...[9:00:00 AM ET]DVN$51.27-0.37(-0.72%)NEQ Operating Strengthens Leadership Team to Support Next Phase of Growth[9:00:00 AM ET]SSBI$12.00-0.10(-0.83%)Summit State Bank Reports Third Quarter 2026 Financial Results[9:00:00 AM ET]QVCG$7.28-0.85(-10.46%)HSN Announces Michelle Buteau, Christie Brinkley, Curtis Stone and Dr. Paul Nassif as 'Holiday Helpers' for the Season HSN®, a leader in live social shopping and video storytelling, is making the holiday season more joyful and effortless with the launch of HSN Holiday ...[9:00:00 AM ET]IPST$2.13+0.09(+4.46%)IP Strategy Holdings, Inc. Regains Compliance with Nasdaq Listing Rule[9:00:00 AM ET]

MDGL · NASDAQ

Madrigal Pharmaceuticals, Inc.

$437.74 -0.02 (0.00%)

Company overview

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-beta agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has a research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$10.1B
Employees
528
Headquarters
West Conshohocken, PA
Website
madrigalpharma.com
CEO
William J. Sibold
Listed
February 6, 2007
P/E
-34.20
Dividend yield
0.00%

Company financials

Revenue
$1.1B
Gross profit
$1.1B
Operating income
-$314M
EBITDA
-$288M
Net income
-$309M
EPS
-$12.80
Total assets
$1.2B
Total debt
$347M
Gross margin
93.07%
Net margin
-27.32%
Earnings yield
-2.92%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

427.86464.62501.38538.13574.89
MDGL 1D NASDAQ O435.49H442.99L435.49C437.76+3.52 (+0.81%)Vol62.61K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
MDGLMadrigal Pharmaceuticals, Inc. Press release Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH GlobeNewswire
MDGLMadrigal Pharmaceuticals, Inc. Stock news Baron Health Care Fund: Q3 2026 New Positions And Exits Seeking Alpha
MDGLMadrigal Pharmaceuticals, Inc. Press release Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
MDGLMadrigal Pharmaceuticals, Inc. Stock news Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL) Defense World
MDGLMadrigal Pharmaceuticals, Inc. Press release Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants GlobeNewsWire
MDGLMadrigal Pharmaceuticals, Inc. Press release Madrigal Pharmaceuticals Announces Grants of Inducement GlobeNewswire
MDGLMadrigal Pharmaceuticals, Inc. Stock news Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Seeking Alpha
MDGLMadrigal Pharmaceuticals, Inc. Stock news Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? The Motley Fool
MDGLMadrigal Pharmaceuticals, Inc. Press release Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference GlobeNewsWire
MDGLMadrigal Pharmaceuticals, Inc. Stock news Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of “Moderate Buy” by Analysts Defense World
MDGLMadrigal Pharmaceuticals, Inc. Stock news Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off The Motley Fool
MDGLMadrigal Pharmaceuticals, Inc. Stock news Allworth Financial LP Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL Defense World
MDGLMadrigal Pharmaceuticals, Inc. Stock news Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands Defense World
MDGLMadrigal Pharmaceuticals, Inc. Stock news Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands MarketBeat
MDGLMadrigal Pharmaceuticals, Inc. Stock news John Paulson's Top Q2 2026 Move: Exiting Agnico Eagle Mines Ltd at a -5.11% Portfolio Impact GuruFocus
MDGLMadrigal Pharmaceuticals, Inc. Press release Madrigal Appoints John C. Reed, M.D. GlobeNewsWire
MDGLMadrigal Pharmaceuticals, Inc. Stock news Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Seeking Alpha
MDGLMadrigal Pharmaceuticals, Inc. Press release Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference GlobeNewsWire
MDGLMadrigal Pharmaceuticals, Inc. Press release Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 GlobeNewsWire
MDGLMadrigal Pharmaceuticals, Inc. Press release Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio GlobeNewsWire
See more
FAQ

Questions about Madrigal Pharmaceuticals, Inc.

What does Madrigal Pharmaceuticals, Inc. do?
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-beta agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has a research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
What is MDGL's market cap?
Madrigal Pharmaceuticals, Inc. (MDGL) is a listed stock with a live quote. The latest market cap on this page is $10.1B.
Where is Madrigal Pharmaceuticals, Inc. headquartered?
Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, PA.
How do I get MDGL news from the API?
Call GET /v1/news?tickers=MDGL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does MDGL news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MDGL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the MDGL price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs